The use of multi-parametric magnetic resonance imaging (mpMRI) in conjunction with the Prostate Imaging Reporting and Data System (PI-RADS) is standard practice in the diagnosis, surveillance, and staging of prostate cancer. The risk associated with lesions graded at a PI-RADS score of 3 is ambiguous. Further characterization of the risk associated with PI-RADS 3 lesions would be useful in guiding further work-up and intervention. This study aims to better characterize the utility of PI-RADS 3 and associated risk factors in detecting clinically significant prostate cancer. From a prospectively maintained IRB-approved dataset of all veterans undergoing mpMRI fusion biopsy at the Southeastern Louisiana Veterans Healthcare System, we identified a cohort of 230 PI-RADS 3 lesions from a dataset of 283 consecutive UroNav-guided biopsies in 263 patients from October 2017 to July 2020. Clinically significant prostate cancer (Gleason Grade ≥ 2) was detected in 18 of the biopsied PI-RADS 3 lesions, representing 7.8% of the overall sample. Based on binomial analysis, PSA densities of 0.15 or greater were predictive of clinically significant disease, as was PSA. The location of the lesion within the prostate was not shown to be a statistically significant predictor of prostate cancer overall (p = 0.87), or of clinically significant disease (p = 0.16). The majority of PI-RADS 3 lesions do not represent clinically significant disease; therefore, it is possible to reduce morbidity through biopsy. PSA density is a potential adjunctive factor in deciding which patients with PI-RADS 3 lesions require biopsy. Furthermore, while the risk of prostate cancer for African-American men has been debated in the literature, our findings indicate that race is not predictive of identifying prostate cancer, with comparable Gleason grade distributions on histology between races.
This study aimed to evaluate if race impacted outcomes or risk of disease progression in men on active surveillance (AS) for prostate cancer. We present the results from our majority African-American cohort of men in an equal access setting over a 5-year follow-up period. All patients who elected AS for prostate cancer at the Southeast Louisiana Veterans Health Care System are entered into a prospectively managed observational database. Patients were divided into groups based on self-reported race. Grade group progression was defined as pathologic upgrading above International Society of Urological Pathology Grade Group 1 disease on subsequent biopsies following diagnostic biopsy. All tests were 2 sided using a significance of .05. A total of 228 men met inclusion criteria in the study, including 154 non-Hispanic African American and 74 non-Hispanic Caucasian American men, with a median follow-up of 5 years from the initiation of AS. Race was not predictive of Gleason grade progression, AS discontinuation, or biochemical recurrence on Cox multivariate analysis (HR = 1.01, 0.94, 0.85, P = .96, .79, .81, respectively). On Kaplan-Meier analysis at 5 years, African-American progression-free, AS discontinuation free, and overall survival probability was comparable to their Caucasian American counterparts (P > .05 for all). Active surveillance is a safe treatment option for low and very low risk prostate cancer, regardless of race. African-American and Caucasian-American men did not have any significant difference in Gleason grade group progression in our cohort with 5-year follow-up.
Introduction: Peyronie's Disease (PD) is characterized by physical deformity in the penis that often has a negative impact on the sexual relationship of the patient and his partner. The International Index of Erectile Function (IIEF) is a standardized patient questionnaire used to measure various aspects of erectile performance and the severity of erectile dysfunction. IIEF accuracy in patients with Peyronie's disease has been criticized as the questions that compromise this tool inquire about sexual activity and intercourse in the patient over the past 30 days, not considering the fact that those patients are able to achieve adequate erection for intercourse but do not engage either due to physical difficulty due to curvature or psychological stress, hence misrepresenting the degree of erectile dysfunction. Objective: In this study, we correlate the IIEF score domain with the presence of vascular abnormalities on penile duplex doppler ultrasound (PDDU) during the evaluation of patients for PD. Methods: We evaluate all patients presenting with symptoms suggestive of PD with a PDDU for better counseling on different treatment options. The IIEF questionnaire is filled at the beginning of each study. Arterial insufficiency is characterized by peak systolic velocity (PSV) less than 30 ml/sec, while venous leak is characterized by end-diastolic velocity (EDV) more than 5 ml/sec. Those measurements are obtained at 10, 15 and 20 min after injecting intracevrnosal vasoactive agent, while recording the tumescence and rigidity at each time point. In addition, we correlate the severity of IIEF score with the prevalence of vascular abnormalities detected in the PDDU study. Results: 540 consecutive patients between January 2016 and December 2020 were included in this study. The mean age of the cohort was 55.1 years. The average curvature was 53.3 degrees, with mean tumescence and rigidity achieved 90% and 70.6%, respectively. Graph 1 shows the distribution of the different vascular abnormalities detected on the PDDU in each category of IIEF abnormality. There is a clear decreasing trend of finding non-vascular abnormalities as the IIEF value decrease from None to Severe (Figure 1). Additionally, there is concomitant rise in the amount of arterial insufficiency and venous leak (counting venous leak and mixed etiology) as the severity measured on IIED questionnaire increases. Conclusions: While IIEF questionnaire has been criticized in patients with PD as being an inaccurate assessment of erectile function, it seems to still be of a value and roughly correlates with PDDU findings. After analyzing data from our cohort, IIEF has the potential assist in treatment decision making as a screening tool for need of additional tests with higher specificity. Disclosure: Any of the authors act as a consultant, employee or shareholder of an industry for: Endo Pharma
UNSTRUCTURED Extra-appendiceal mucinous neoplasms (EAMNs) are rare mucin-producing tumors that share histopathologic features with appendiceal mucinous neoplasms but arise outside the appendix. Their occurrence in the anal region is exceedingly uncommon and poses significant diagnostic and therapeutic challenges. We report the case of a 76-year-old male with a prior history of T3N0M0 anal mucinous adenocarcinoma treated with chemoradiation with complete clinical response found eight years later on surveillance exam and colonoscopy to have a recurrent anal mass. Subsequent imaging with PET-CT and pelvic MRI demonstrated a lesion involving the distal anal canal with extension into perianal tissues and invasion of the internal sphincter complex. Initial biopsy revealed mucinous adenocarcinoma. Following multidisciplinary evaluation, the patient underwent robotic-assisted abdominoperineal resection (APR) and reconstruction using a vertical rectus abdominis myocutaneous (VRAM) flap. Final histopathologic analysis revealed a low-grade mucinous proliferation with adenoma-like architecture and pushing borders. These morphologic features were more consistent with an extra-appendiceal mucinous neoplasm rather than recurrent invasive carcinoma. This case highlights the diagnostic complexity of mucinous lesions in the anal region, particularly in the context of prior malignancy and fistulous disease. EAMNs should be considered in the differential diagnosis of atypical anal tumors. Radical surgical resection with appropriate reconstructive techniques remains the cornerstone of management, although further studies are needed to better define the pathogenesis and optimal treatment strategies for these rare neoplasms.